Back to Journals » Therapeutics and Clinical Risk Management » Volume 14

Exploring the effect of chidamide on blastic plasmacytoid dendritic cell neoplasm: a case report and literature review

Authors Wang S, Guo W, Wan X, Teng Y, Zhou X, Bai O

Received 6 November 2017

Accepted for publication 29 November 2017

Published 3 January 2018 Volume 2018:14 Pages 47—51


Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2

Editor who approved publication: Professor Deyun Wang

Shunan Wang,1 Wei Guo,1 Xin Wan,1 Yongliang Teng,2 Xiaoge Zhou,3 Ou Bai1

1Department of Hematology, 2Department of Pathology, The First Hospital of Jilin University, Changchun, 3Department of Pathology, Beijing Friendship Hospital, Capital Medical University, Beijing, People’s Republic of China

Abstract: Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive hematopoietic malignancy mainly affecting elderly patients. It is highly responsive to chemotherapy, but the median event-free survival is very short and has a high rate of relapse even after performing allogeneic stem cell transplantation; thus, the discovery of novel agents for the treatment of BPDCN is urgent. Chidamide is a new oral isotype-selective histone deacetylase inhibitor (HDACi). It is proved to exert a well-characterized anticancer property in a wide range of hematological malignancies, especially lymphoma. Here, we report a 41-year-old man who used oral chidamide 30 mg twice per week for maintenance therapy after receiving complete remission. For the first time in this field, we had explored the efficiency of chidamide in the treatment of BPDCN and tried to give more choices to the therapy of this disease.

Keywords: hematopoietic malignancy, skin lesions, maintenance therapy, histone deacetylase inhibitor

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]